Prevention of shingles in cancer patients is critical due to their increased risk and potential for severe complications. The shingles vaccine is recommended for adults over 50, but its use in cancer patients should be discussed with a healthcare provider, as timing and type of vaccine (live vs. recombinant) can be crucial based on their treatment status. The recombinant zoster vaccine (RZV) is often preferred for immunocompromised individuals.
